Literature DB >> 20558144

Assessing the prevalence of PINK1 genetic variants in South African patients diagnosed with early- and late-onset Parkinson's disease.

Rowena J Keyser1, Suzanne Lesage, Alexis Brice, Jonathan Carr, Soraya Bardien.   

Abstract

Mutations in the PINK1 gene are the second most common cause after parkin of autosomal recessive early-onset Parkinson's disease (PD). PINK1 is a protein kinase that is localized to the mitochondrion and is ubiquitously expressed in the human brain. Recent studies aimed at elucidating the function of PINK1, have found that it has neuroprotective properties against mitochondrial dysfunction and proteasomally-induced apoptosis. In the present study, we aimed to investigate the prevalence of PINK1 genetic variants in 154 South African PD patients from all ethnic groups. Mutation screening was performed using the High-Resolution Melt technique and direct sequencing. A total of 16 sequence variants were identified: one known homozygous mutation (Y258X), two heterozygous missense variants (P305A and E476K), and 13 polymorphisms of which five were novel. No homozygous exonic deletions were detected. The novel P305A variant was found in a female patient of Black Xhosa ethnicity who has a positive family history of the disease and an age at onset of 30years. This variant has the potential to modulate enzymatic activity due to its location in the kinase domain. This is the first report on mutation screening of PINK1 in the South African population. Results from the present study showed that point mutations and homozygous exonic deletions in PINK1 are not a common cause of PD in the South African population. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20558144     DOI: 10.1016/j.bbrc.2010.06.049

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

Review 1.  Epidemiology of neurodegenerative diseases in sub-Saharan Africa: a systematic review.

Authors:  Alain Lekoubou; Justin B Echouffo-Tcheugui; Andre P Kengne
Journal:  BMC Public Health       Date:  2014-06-26       Impact factor: 3.295

2.  Identification of Parkinson's disease candidate genes using CAESAR and screening of MAPT and SNCAIP in South African Parkinson's disease patients.

Authors:  Rowena J Keyser; Ekow Oppon; Jonathan A Carr; Soraya Bardien
Journal:  J Neural Transm (Vienna)       Date:  2011-02-23       Impact factor: 3.575

3.  Neurexin 2 p.G849D variant, implicated in Parkinson's disease, increases reactive oxygen species, and reduces cell viability and mitochondrial membrane potential in SH-SY5Y cells.

Authors:  Katelyn Cuttler; Dalene de Swardt; Lize Engelbrecht; Jurgen Kriel; Ruben Cloete; Soraya Bardien
Journal:  J Neural Transm (Vienna)       Date:  2022-10-15       Impact factor: 3.850

4.  A molecular analysis of the GBA gene in Caucasian South Africans with Parkinson's disease.

Authors:  Melinda Barkhuizen; David G Anderson; Francois H van der Westhuizen; Anne F Grobler
Journal:  Mol Genet Genomic Med       Date:  2017-02-08       Impact factor: 2.183

5.  T313M polymorphism of the PINK1 gene in Parkinson's disease.

Authors:  Qin Luo; Xinling Yang; Yani Yao; Hongjuan Li; Yuling Wang
Journal:  Exp Ther Med       Date:  2014-05-08       Impact factor: 2.447

Review 6.  Parkinson's Disease in Sub-Saharan Africa: A Review of Epidemiology, Genetics and Access to Care.

Authors:  Uduak Williams; Oliver Bandmann; Richard Walker
Journal:  J Mov Disord       Date:  2018-05-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.